沙利度胺联合化疗对EGFR野生型晚期非小细胞肺癌的影响  

Effect of Thalidomide Combined with Chemotherapy on Wild-typeAdvanced Non-small Cell Lung Cancer of EGFR

作　　者：王娟[1] 张朝阳 汪子书[1] 曾会会 赵论[1] 何泽来 苏方[1] Wang Juan;Zhang Chaoyang;Wang Zishu;Zeng Huihui;Zhao Lun;He Zelai;Su Fang(Department of Oncology,the First Affiliated Hospital of Bengbu Medical College;Department of Clinical Trial Center,the First Affiliated Hospital of Bengbu Medical College;Department of Radiotherapy,the First Affiliated Hospital of Bengbu Medical College,Bengbu 233000 China)

机构地区：[1]蚌埠医学院第一附属医院肿瘤内科 [2]蚌埠医学院第一附属医院临床试验中心 [3]蚌埠医学院第一附属医院放疗科,安徽蚌埠233000

出　　处：《锦州医科大学学报》2023年第5期42-46,共5页Journal of Jinzhou Medical University

基　　金：蚌埠医学院自然重点项目,项目编号:2020byzd155;安徽高校自然科学研究重点项目,项目编号:KJ2021A0692。

摘　　要：目的 观察沙利度胺联合化疗治疗表皮生长因子受体(epidermal growth factor receptor, EGFR)野生型晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的生活质量评分、不良反应发生率以及对血清血管内皮生长因子(vascular endothelial growth factor, VEGF)水平的影响。方法 纳入2021年1月至2022年12月在蚌埠医学院第一附属医院肿瘤内科接受治疗的EGFR野生型晚期NSCLC患者,共纳入100例。观察组为采用沙利度胺联合含铂两药化疗治疗患者;对照组为单用含铂两药化疗治疗的患者。观察组共纳入58例患者,给予含铂两药化疗方案治疗;同时口服沙利度胺片100 mg,每日一次,睡前服用;对照组共纳入42例患者,给予化疗方案剂量同上,两组化疗前常规给予止吐药物预防性治疗。比较用药后第7~14天两组患者生活质量各领域评分;比较两组患者治疗期间不良反应发生率;比较两组患者治疗后血清VEGF水平差异。结果 观察组患者第7~14天的躯体(79.18±8.59 vs 64.94±8.60)、角色(71.82±14.05 vs 59.00±12.10)、情绪功能(81.94±15.95 vs 69.71±11.38)、认知(74.53±11.74 vs 59.56±8.75)、社会功能(82.24±13.70 vs 66.82±10.11)和总体健康状况评分(70.81±9.67 vs 60.11±8.77)较对照组患者均明显提高,差异有统计学意义(P<0.05);疲倦(28.08±13.09 vs 38.53±14.23)、疼痛(27.44±8.17 vs 39.19±10.13)、失眠(38.07±12.12 vs 45.23±16.61)和食欲丧失症状评分(40.46±13.70 vs 47.61±17.15)则显著低于对照组,差异有统计学意义(P<0.05);两组间恶心呕吐、气促、便秘、腹泻和经济困难差异无统计学意义(P>0.05);观察组患者化疗期间白细胞及血小板下降不良反应发生率低于对照组(20/58 vs 27/42;P<0.05);两组患者血清VEGF水平比较,观察组水平低于对照组,且差异有统计学意义(127.35±126.03 vs 183.86±120.55;P<0.05)。结论 沙利度胺对EGFR野生型晚期非小细胞肺癌化疗期间的生活质量起到改善作用Objective To observe the effects of thalidomide combined with chemotherapy on quality of life score,incidence of adverse reactions and serum VEGF levels in patients with EGFR wild-type advanced NSCLC.Methods A total of 100 patients with EGFR wild-type advanced NSCLC who received treatment in the Department of Oncology of the First Affiliated Hospital of Bengbu Medical College from January 2021 to December 2022 were included.Observation group was treated with thalidomide combined with platinum two-drug chemotherapy;the control group was treated with platinum-containing two-drug chemotherapy alone.A total of 58 patients in the observation group were included and given platinum-containing two-drug chemotherapy regimen.At the same time oral thalidomide tablets 100mg qd before bedtime;a total of 42 patients in the control group were included,and the dose of chemotherapy was the same as above.The two groups were routinely given preventive treatment with antiemetic drugs before chemotherapy.The quality of life scores in all fields were compared between the two groups on 7-14 days after medication.The incidence of adverse reactions during treatment was compared between the two groups.Serum VEGF levels were compared between the two groups after treatment.Results The somatic(79.18±8.59 vs 64.94±8.60),role(71.82±14.05 vs 59.00±12.10),emotional function(81.94±15.95 vs 69.71±11.38),cognition(74.53±11.74 vs 59.56±8.75),social function(82.24±13.70 vs 66.82±10.11)and overall health status(70.81±9.67 vs 60.11±8.77)of the observation group on 7 to 14 days were significantly improved(P<0.05).The symptoms of fatigue(28.08±13.09 vs 38.53±14.23),pain(27.44±8.17 vs 39.19±10.13),insomnia(38.07±12.12 vs 45.23±16.61)and loss of appetite(40.46±13.70 vs 47.61±17.15)were significantly lower than those in control group(P<0.05);the differences in nausea,vomiting,shortness of breath,constipation,diarrhea and economic difficulties between the two groups had no statistical significance(P>0.05);the incidence of adverse reaction

关 键 词：沙利度胺 晚期非小细胞肺癌 EGFR野生型 血管内皮生长因子 

分 类 号：R734.2[医药卫生—肿瘤]